WitrynaNovartis Confidential Page 4 Package Insert Gleevec™ (imatinib mesylate) 80 CYP3A4 substrates: Imatinib increased the mean Cmax and AUC of simvastatin (CYP3A4 … WitrynaThese highlights do not include all the information needed to use Gleevec safely and effectively. See full prescribing information for Gleevec. GLEEVEC (imatinib …
Important Safety Information on BCR-ABL Tyrosine Kinase …
Witryna21 gru 2024 · Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective … Witryna11 kwi 2024 · The drug, named STI-571 and later renamed imatinib (Gleevec), blocks the activity of the BCR-ABL fusion protein. In 1998, Dr. Druker and his colleagues … culver city rock and gem show
Imatinib Mesylate C30H35N7O4S - PubChem
WitrynaImatinib mesylate (IM) represents the first-line treatment of patients with chronic myeloid leukemia (CLM) or gastrointestinal stromal tumor (GIST). It presents several side effects. However, less than 10% are nonhematologic including nausea, vomiting, diarrhea, muscle cramps, and cutaneous reactions. WitrynaTreatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag 2008; 4: 149-62. 5. Dulucq S, Krajinovic M. The pharmacogenetics of imatinib. ... Krebs-Brown A, Capdeville R, Keller U, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI 571) in healthy subjects. Cancer Chemother ... WitrynaGeneric Name Imatinib DrugBank Accession Number DB00619 Background. Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, … easton animal clinic hours